Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | 225Ac-DOTA-Daratumumab |
Trade Name | |
Synonyms | [225Ac]-DOTA-Daratumumab |
Drug Descriptions |
225Ac-DOTA-Daratumumab is a radioconjugate comprising daratumumab, a monoclonal antibody that targets CD38, linked to the radionuclide Actinium-225, which delivers radiation to tumor cells, potentially resulting in cytotoxic effects and inhibition of tumor growth (PMID: 31413916, NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C186744 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
225Ac-DOTA-Daratumumab | 225Ac-DOTA-Daratumumab | 0 | 2 |